Decision: Favourable

Study Title:

A multicentre, randomized, double-blind, placebo-controlled, parallel- group phase 3 study to evaluate the safety and efficacy of masitinib as add-on therapy in patients with mild to moderate Alzheimer’s disease, treated with standard of care: cholinesterase inhibitors, memantine 

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT application

  • Principal Investigator:

    Prof Sean Kennelly

  • PI Institution:

    Tallaght Hospital

  • Sponsor:

    AB Science

Scroll to Top